Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective / Allen, P.b., Bonovas, S., Danese, S., Peyrin-Biroulet, L.. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - 20:2(2020), pp. 151-161. [10.1080/14712598.2020.1702020]
Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective
Danese S;
2020-01-01
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD an historical perspective.pdf
solo gestori archivio
Dimensione
1.11 MB
Formato
Adobe PDF
|
1.11 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
